Search Results for: AR

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
GLI2 GLI family zinc finger 2
  • Degradation of GLI2 by the proteasome
  • Hedgehog 'off' state
  • Hedgehog 'on' state
  • GLI proteins bind promoters of Hh responsive genes to promote transcription
  • RUNX2 regulates chondrocyte maturation
  • Holoprosencephaly (HPE)
HDAC4 histone deacetylase 4
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Notch-HLH transcription pathway
  • SUMOylation of intracellular receptors
  • SUMOylation of chromatin organization proteins
  • RUNX2 regulates chondrocyte maturation
  • RUNX3 regulates p14-ARF
  • Zinc
  • Belinostat
  • Romidepsin
  • Panobinostat
  • N-hydroxy-5-[(3-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)carbonyl]thiophene-2-carboxamide
  • 2,2,2-TRIFLUORO-1-{5-[(3-PHENYL-5,6-DIHYDROIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL)CARBONYL]THIOPHEN-2-YL}ETHANE-1,1-DIOL
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Brachydacytly-mental retardation syndrome and Smith-Magenis syndrome
LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
MLH3 mutL homolog 3
  • Meiotic recombination
  • Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome
NCOA4 nuclear receptor coactivator 4
  • Thyroid cancer
NR3C1 nuclear receptor subfamily 3 group C member 1
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • Circadian Clock
  • SUMOylation of intracellular receptors
  • PTK6 Expression
  • Regulation of RUNX2 expression and activity
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Potential therapeutics for SARS
  • Flunisolide
  • Diflorasone
  • Alclometasone
  • Medrysone
  • Amcinonide
  • Fluorometholone
  • Megestrol acetate
  • Levonorgestrel
  • Beclomethasone dipropionate
  • Progesterone
  • Spironolactone
  • Betamethasone
  • Desoximetasone
  • Fluticasone propionate
  • Fluocinolone acetonide
  • Ulobetasol
  • Triamcinolone
  • Prednisone
  • Flumethasone
  • Fludrocortisone
  • Norethisterone
  • Hydrocortisone
  • Mometasone
  • Hydrocortamate
  • Mifepristone
  • Clocortolone
  • Flurandrenolide
  • Prednisolone
  • Loteprednol etabonate
  • Rimexolone
  • Methylprednisolone
  • Clobetasol propionate
  • Fluocinonide
  • Prednicarbate
  • Fluoxymesterone
  • Budesonide
  • Dexamethasone
  • Desonide
  • Cortisone acetate
  • Paramethasone
  • Drospirenone
  • Ciclesonide
  • Hexane-1,6-Diol
  • Aldosterone
  • ORG-34517
  • Difluprednate
  • Ulipristal
  • Fluticasone furoate
  • Tixocortol
  • Difluocortolone
  • Gestrinone
  • Deflazacort
  • Onapristone
  • Cortivazol
  • Clobetasone
  • Fluticasone
  • Mometasone furoate
  • Hydrocortisone aceponate
  • Hydrocortisone acetate
  • Hydrocortisone butyrate
  • Hydrocortisone cypionate
  • Hydrocortisone phosphate
  • Hydrocortisone probutate
  • Hydrocortisone valerate
  • Segesterone acetate
  • Prednisolone phosphate
  • Dexamethasone acetate
  • Betamethasone phosphate
  • Prednisolone acetate
  • 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
NSD2 nuclear receptor binding SET domain protein 2
  • PKMTs methylate histone lysines
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • G2/M DNA damage checkpoint
  • Multiple myeloma
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
REL REL proto-oncogene, NF-kB subunit
  • Activation of NF-kappaB in B cells
  • Hodgkin lymphoma
RUNX2 RUNX family transcription factor 2
  • Cleidocranial dysplasia
SART3 spliceosome associated factor 3, U4/U6 recycling protein
  • Disseminated superficial actinic porokeratosis (DSAP)
SH2D1A SH2 domain containing 1A
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
TBP TATA-box binding protein
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • SIRT1 negatively regulates rRNA expression
  • NoRC negatively regulates rRNA expression
  • B-WICH complex positively regulates rRNA expression
  • RNA Polymerase II Pre-transcription Events
  • Regulation of TP53 Activity through Phosphorylation
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase III Abortive And Retractive Initiation
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • Estrogen-dependent gene expression
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
TCF4 transcription factor 4
  • Myogenesis
  • Myogenesis
  • Pitt-Hopkins syndrome, including: Pitt-Hopkins syndrome; Pitt-Hopkins-like syndrome
TCF7L2 transcription factor 7 like 2
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Repression of WNT target genes
  • Repression of WNT target genes
  • Signaling by TCF7L2 mutants
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates WNT signaling
  • Type II diabetes mellitus
TGIF1 TGFB induced factor homeobox 1
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Holoprosencephaly (HPE)
UBE3A ubiquitin protein ligase E3A
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Prader-Willi and Angelman syndromes, including: Angelman syndrome (AS); Prader-Willi syndrome (PWS)
VCP valosin containing protein
  • Translesion Synthesis by POLH
  • HSF1 activation
  • ABC-family proteins mediated transport
  • N-glycan trimming in the ER and Calnexin/Calreticulin cycle
  • Hedgehog ligand biogenesis
  • Hh mutants are degraded by ERAD
  • Defective CFTR causes cystic fibrosis
  • Josephin domain DUBs
  • Ovarian tumor domain proteases
  • Neutrophil degranulation
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Protein methylation
  • Aggrephagy
  • Attachment and Entry
  • Attachment and Entry
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Phenethyl Isothiocyanate
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • Negative regulation of FLT3
  • ATP
  • Dasatinib
  • XL228
  • K-00546
  • Fostamatinib
AHR aryl hydrocarbon receptor
  • PPARA activates gene expression
  • Phase I - Functionalization of compounds
  • Endogenous sterols
  • Xenobiotics
  • Aryl hydrocarbon receptor signalling
  • Omeprazole
  • Mexiletine
  • Nimodipine
  • Flutamide
  • Atorvastatin
  • Leflunomide
  • Ginseng
  • Indirubin-3'-monoxime
  • Resveratrol
  • Quercetin
  • beta-Naphthoflavone
  • Emodin
  • 1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine
  • Diosmin
  • Indigotindisulfonic acid
  • Kynurenic Acid
  • Epigallocatechin gallate
  • Cantharidin
  • Indirubin

Page 3 out of 14 pages